Allcyte is a biotech startup founded in 2017 that developed the Pharmacoscopy platform—a high-content imaging technology combining advanced microscopy and AI to test drug efficacy in fresh, primary human cancer tissues.[1][2][3][4] It serves pharmaceutical companies and physicians by identifying optimal drugs for specific patients, supporting preclinical drug development, clinical decision-making, and repurposing existing therapies for new cancer indications.[1][3] The platform addresses precision oncology challenges by directly querying tumors for effective treatments, bypassing less reliable DNA-based predictions, which improves clinical trial success and patient outcomes.[2][3] Allcyte raised $6M in funding before its acquisition by Exscientia in June 2021, marking strong early momentum in AI-driven drug discovery.[1][2][3]
Allcyte emerged from the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, where its founders collaborated on innovative cancer research.[1][3] Co-founders include Nikolas Krall (CEO, chemist), Gregory Vladimer (CSO, immunologist), Berend Snijder, and Giulio Superti-Furga (both molecular biologists), who spun out the company in 2017 after developing Pharmacoscopy from their work on functional drug testing in primary human tissues.[3] Headquartered at Campus Vienna Biocenter, the idea stemmed from recognizing limitations in traditional extrapolations from DNA sequencing, instead using real tumor samples for direct, AI-analyzed responses to drugs.[3] Early traction included partnerships with 10 major pharma firms like Boehringer Ingelheim and a $6M funding round in 2021 from investors such as Air Street Capital and 42CAP, culminating in its acquisition by Exscientia.[2][3]
Allcyte rides the AI-precision oncology wave, where tech accelerates personalized cancer therapies amid rising demands for efficient drug development and real-world evidence.[2][3] Its timing aligns with post-2020 surges in AI-biotech investments, as firms seek tools to de-risk clinical trials amid high failure rates (over 90% for oncology drugs).[3] Market forces like aging populations, patent cliffs on legacy drugs, and regulatory pushes for precision medicine favor its tumor-direct approach, differentiating it from genomics-heavy competitors like Biodesix or Lantern Pharma.[3] Post-acquisition, Allcyte influences Exscientia's ecosystem by enhancing AI-driven pipelines, contributing to broader shifts toward functional assays in digital health and oncology tech collections.[1][2]
Integrated into Exscientia since 2021, Allcyte's Pharmacoscopy will likely expand within larger AI-pharma platforms, powering more clinical validations and partnerships.[1][2] Trends like multimodal AI (imaging + genomics) and real-world data integration will shape its evolution, potentially boosting Exscientia's trial success rates amid a projected $100B+ precision oncology market.[3] Its influence may grow by standardizing functional testing, evolving from startup innovator to core tool in global drug discovery—reinforcing how tissue-based AI unlocks "right drug, right patient" at scale, as pioneered in Vienna.[1][3]
Allcyte has raised $6.0M in total across 1 funding round.
Allcyte's investors include Air Street Capital, Amino Collective, Band of Angels, Bornschein & keine Töchter, Philipp Herkelmann.
Allcyte has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in June 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2020 | $6.0M Seed | Air Street Capital, Amino Collective, Band of Angels, Bornschein & keine Töchter, Philipp Herkelmann |
